# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 2161-2170 of 2218 results.
Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Completed
Last Changed: Jun 15, 2017
First Received: Jan 01, 2009
Disease(s): Leukemia, Lymphoma
Intervention(s): bevacizumab, pegfilgrastim, rituximab, cyclophosphamide, pentostatin
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Mayo Clinic, Rochester, Minnesota, United States
Safety Study of NHL With 90Y-hLL2 IgG
Status: Completed
Last Changed: Jan 18, 2008
First Received: Jan 12, 2007
Disease(s): NHL, B-Cell NHL, Non-Hodgkins Lymphoma
Intervention(s): 90Y-hLL2
Locations: Research Unit 463 INSERM, Nantes, Cedex, France
Service des Maladies du Sang, Lille, France
University Hospital Dresden, Dresden, Germany
Klinikum der Georg-August-Universitat Gottingen, Gottingen, Germany
Universitatsklinikum University of Saarland, Homburg/Saar, Germany
... and 1 other locations.
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
Status: Active, not recruiting
Last Changed: Sep 30, 2020
First Received: Jan 05, 2017
Disease(s): Anemia, B-Cell Prolymphocytic Leukemia, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Hairy Cell Leukemia, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Richter Syndrome
Intervention(s): Entospletinib, Laboratory Biomarker Analysis, Obinutuzumab, Pharmacological Study
Locations: OHSU Knight Cancer Institute, Portland, Oregon, United States
In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
Status: Recruiting
Last Changed: Feb 11, 2020
First Received: Sep 08, 2011
Disease(s): Acute Lymphocytic Leukemia, Lymphoma
Intervention(s): Biological/Genetically Modified T cells, Cyclophosphamide-based chemotherapy
Locations: Memorial Sloan Kettering Cancer Center, New York, New York, United States
Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia
Status: Completed
Last Changed: Sep 14, 2017
First Received: May 04, 2010
Disease(s): Leukemia, Lymphoid, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Intervention(s): Lenalidomide plus dexamethasone
Locations: CHU de Clermont-Ferrand, Clermont-Ferrand, France
Hôpital Michallon, Grenoble, France
Hôpital Edouard Herriot, Lyon, France
Institut de Cancerologie de la Loire, St Priest en Jarez, France
Enhancing Diagnosis in Chronic B-cell Lymphoproliferative Disorders Using Next-Generation Sequencing
Status: Unknown status
Last Changed: Nov 17, 2017
First Received: Nov 17, 2017
Disease(s): Lymphoma
Locations: The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies
Status: Recruiting
Last Changed: Dec 03, 2019
First Received: Dec 03, 2019
Disease(s): B Acute Lymphoblastic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma
Intervention(s): CD19-CART
Locations: Hematology Department of the Second Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China
Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Terminated
Last Changed: Nov 11, 2015
First Received: Feb 26, 2010
Disease(s): Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Small Lymphocytic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma
Intervention(s): Alvocidib Hydrochloride, Cyclophosphamide, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study, Rituximab
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
Status: Recruiting
Last Changed: Sep 14, 2020
First Received: Dec 12, 2014
Disease(s): Follicular Lymphoma, ALL, NHL, Large Cell Lymphoma
Intervention(s): CD22-CAR
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies
Status: Active, not recruiting
Last Changed: Jun 01, 2020
First Received: May 12, 2017
Disease(s): B Cells-Tumors, B Cell Chronic Lymphocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Large B-Cell Diffuse Lymphoma of Bone (Diagnosis)
Intervention(s): Idelalisib 100 MG, Placebo Oral Tablet
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States